The promise of this fourteen gene expression as saying. Is that it may give us additional evidence to help decide whether we're going to treat -- patient with systemic chemotherapy or not. And those patients are the ones that have had surgical or section. This stage one lung cancer patients are our true dilemma. And having a test like this. Not unprecedented we've seen tests such as archetype the -- and Mamo print that have been used for breast cancer patients. They're trying to develop these for colon cancer. This may be a test that we finally can apply in the clinic to our early stage cure cancer patients. Now clearly this is not something I can order tomorrow. On a patient it will require further testing and have to go through the regulatory process. But the hope is because it is very feasible and practical. And has shown some very promising data that this is something that clinicians could utilized to help make treatment decisions for their patients in the near future.

This transcript has been automatically generated and may not be 100% accurate.

Now Playing: Extended 'Obamacare' Deadline Nears End

Now Playing: Glenn Close Uses Star Power to Urge Passing of Mental Health Bill

Now Playing: Kathleen Sebelius Calls for Investigation Into the Healthcare.gov Launch